Estimation of Interleukin-1β Promoter (−31 C/T and −511 T/C) Polymorphisms and Its Level in Coronary Artery Disease Patients

Abstract

Interleukin-1β (IL-1β) is an inflammation-causing cytokine that exerts several unique biological effects and could lead to future adverse events of CAD. The piece of work presented herein is aimed at investigating possible association of IL-1β levels to its polymorphic site viz. -511 and -31 at promoter region in Saudi CAD patients. The study included 155 confirmed CAD patients and 80 healthy control individuals both men and women. Concentration of IL-1β in the patients' serum was measured by ELISA method. For single nucleotide polymorphism (SNP) analysis, sanger method of DNA sequencing was followed. We observed variable numbers of SNPs at -31 C/T and -511 T/C promoter regions in Saudi patients suffering from CAD in comparison to the control set of individuals. However, the changes in the number of SNP-hotspots were determined to be non-significant with reference to the control set. The haplotype analysis at -31 and -511 also did not show any significant changes between control and CAD patients. Moreover, serum IL-1β levels were observed to be expressively higher in patients suffering from CAD (P < 0.001) and its associated complications viz. STEMI (P < 0.001), NSTEMI (P < 0.001), and UA (P < 0.001). Our study provides the status of SNPs at IL-1β promoter in Saudi population. As per our information, ours is the first article that shows the genetic diversity in IL-1β promoters and its level in the Saudi CAD patients. J. Cell. Biochem. 118: 2977-2982, 2017. © 2017 Wiley Periodicals, Inc.

A putative association of interleukin‐10 promoter polymorphisms with cardiovascular disease

“…In our earlier studies, we reported non‐significant associations of SNPs in promoter region of IL‐6, IL‐18, and IL‐1β genes with Saudi CVD patients . However, the present study reports a significant association between polymorphism in IL‐10 promoters at −1082 and −819 sites with Saudi CVD patients.…”

“…In our earlier studies, we have reported a significant elevation in different inflammatory mediators such as IL‐6, IL‐18, and IL‐1β in Saudi CVD patients . In this study too, we observed a significant elevation in IL‐10 level in CVD patients and other cardiac events (Table ).…”

The interplay between microbiota‐dependent metabolite trimethylamine N‐oxide, Transforming growth factor β/SMAD signaling and inflammasome activation in chronic kidney disease patients: A new mechanistic perspective

“…NLRP3 activation and consequent inflammation‐causing cytokine interleukin‐1β (IL‐1β) secretion are well‐characterized in various types of cells. Although its known protective effect against infections and its importance for proper immune response following tissue damage; excessive inflammasome activation has been linked to plentiful diseases, including cancer and neurodegenerative disorders …”

IL-18 and IL-1β Gene Polymorphisms: The Plausible Risk Factors for Chronic Hepatitis B

“…In contrast to IL-18 gene, IL-1b gene has TATA box, which contains the core promoter region and two important binding sites for the leucine zipper containing transcription factor (TF), CCAAT/enhancer binding protein-b, and the myeloid-specific Ets domain containing TF PU.1 (5,35). It has been reported that IL-1b gene contains several SNPs, including -511 T/C, -1464 C/G, -2023 C/A, -3737 G/A, -31 T/A, +289 C/T, and +3953 C/T, and may be associated with altered expression of the cytokine (20,50,51).…”